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Poor adherence to treatment remains one of the major limita-
tions in the management of hypertension and may contribute 
to increased morbidity, mortality, and costs.1–5 It is estimated 
that at least 50% of the patients with hypertension do not take 
antihypertensive medication as prescribed.6 Several large 
studies have shown that persistence with antihypertensive 
treatment decreases with time: discontinuation rates vary 
from 22% to almost 50% during the first year after initiation 
of therapy.7–10 Therefore, improving adherence to treatment 
remains a major challenge to the treating physician.
Electronic monitoring devices, such as the Medication Event 
Monitoring System (MEMS, Aardex, Zug, Switzerland), have 
been used extensively in assessing adherence to antihyperten-
sive drugs. The advantage of electronic monitoring is that a 
more detailed and accurate information is obtained than can 
be achieved with other methods.11–14 In addition, electronic 
monitoring may improve adherence to treatment, as patients 
are aware of adherence monitoring. Hence, it may improve 
blood pressure (BP) control. Indeed, several studies have dem-
onstrated a positive effect of electronic monitoring of adher-
ence on BP control.15–19 However, most of these studies have 
followed patients for only a short period of time,15–18 making 
it difficult to predict how long the effect of electronic moni-
toring is sustained. Today, only one randomized study inves-
tigated the effect of electronic monitoring on long-term BP 
control.19 Patients whose drug intake was monitored had a 
greater decrease in BP than patients who received usual care. 
However, as adherence results were discussed with the patient 
it is not clear whether the greater reduction in BP is attribut-
able to the electronic monitoring, the discussion with patients, 
or a combination of both.
Therefore, we investigated the effect of electronic monitoring 
of adherence to treatment, without discussing the results with 
the patients, on long-term BP control in patients with mild-to-
moderate hypertension.
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Background
although it is generally acknowledged that electronic monitoring 
of adherence to treatment improves blood pressure (BP) control by 
increasing patients’ awareness to their treatment, little information is 
available on the long-term effect of this intervention.
Methods
In this observational study among a total of 470 patients with mild-
to-moderate hypertension, adherence was measured in 228 patients 
by means of both the Medication Event Monitoring System (MEMS) 
and pill count (intervention group), and in 242 patients by means of 
pill count alone (control group). During a follow-up period of 1 year 
consisting of seven visits to the physician’s office, BP measurements 
were performed and medication adjusted based on the achieved BP. 
In addition, at each visit adherence to treatment was assessed.
results
On the basis of pill counts, median adherence to treatment did 
not differ between the intervention group and the control group 
(96.1% vs. 94.2%; P = 0.97). In both groups, systolic and diastolic BP 
decreased similarly: 23/13 vs. 22/12 mm Hg in the intervention and 
control group respectively. Drug changes and the number of drugs 
used were associated with BP at the start of study, but not with 
electronic monitoring.
conclusions
In this study, electronic monitoring of adherence to treatment by 
means of MEMS did not lead to better long-term BP control nor did it 
result in less drug changes and drug use.
Keywords: adherence; blood pressure; compliance; electronic 
monitoring; hypertension
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Methods
We performed an observational study in which all participating 
patients from the HOMERUS trial were included.20,21 In brief, 
HOMERUS is a multi-centre, prospective, randomized, double 
blind trial with a parallel-group design. Patients, aged 18 years 
and older whose office BP was above 139 mm Hg systolic and/or 
89 mm Hg diastolic were recruited from the outpatient depart-
ments of four participating university hospitals and affiliated 
general practices. If the BP remained above 139/89 mm Hg at 
the second visit, patients were randomly allocated (minimi-
zation procedure) to either the self-pressure (SP) group or the 
office pressure group. If randomized to the SP group antihy-
pertensive treatment was guided by the results of self BP meas-
urement (SBPM). In the office pressure group, treatment was 
titrated on the basis of the office BP measurement. Both pre-
viously treated and untreated patients qualified for inclusion. 
In all of them, secondary hypertension had been ruled out by 
laboratory investigation. At entry into the study, any existing 
antihypertensive therapy was discontinued whenever possible 
and participants entered a placebo run-in period of 4 weeks 
duration before study treatment was initiated. Patients were 
followed-up for seven visits for a period of 1 year. After the third 
visit, patients were followed monthly; after the fifth visit patients 
were followed at a 2-months interval. The primary objective of 
the HOMERUS-study was to examine whether decisions con-
cerning antihypertensive therapy based on SBPM could lead 
to less antihypertensive drugs used and associated costs, when 
compared to decisions based on office BP measurement. As a 
secondary objective, the effect of SBPM on adherence to medi-
cation within random subgroups of the SP and office pressure 
groups was investigated. For this secondary objective, adherence 
to treatment was electronically measured in all patients recruited 
by the coordinating centre (Maastricht University Hospital, 
Maastricht, The Netherlands) and surrounding general practi-
tioners’ practices. All patients gave their informed consent and 
the study was approved by the ethical committees of all partici-
pating centers before inclusion of patients into the study.
BP measurements. At every visit, three consecutive office BP 
measurements were performed in the hospital or at the gen-
eral practitioners clinic. SBPM was performed six times a day 
(three in the morning and three in the evening) for a 7-day 
period, prior to every visit. Patients were requested to register 
their self-measurements on a form and to print out all meas-
urements. Both office BP measurement and SBPM were always 
performed at the nondominant arm in sitting position after 
at least 5 min of rest, using the same fully automated device 
(Omron HEM-705 CP; Omron Healthcare, Kyoto, Japan).22
Study treatment protocol. Treatment was instituted stepwise 
according to the following schedule:
Step 1: Lisinopril 10 mg once daily plus one tablet of placebo 
once daily;
Step 2: Lisinopril 20 mg once daily plus one tablet of placebo 
once daily;
Step 3: Lisinopril 20 mg once daily plus hydrochlorothiazide 
12.5 mg;
Step 4: Lisinopril 20 mg once daily plus hydrochlorothiazide 
12.5 mg plus amlodipine 5 mg.
In both the office pressure and SP group, the goal BP ranged 
between 120 and 139 mm Hg systolic and between 80 and 
89 mm Hg diastolic. In patients who were above the target 
BP (systolic >139 mm Hg and/or diastolic >89 mm Hg), anti-
hypertensive treatment was intensified by one step. If BP was 
lower than the target (systolic <120 mm Hg and diastolic 
<80 mm Hg), treatment was reduced by one step, eventually 
until termination of treatment. If patients were on their target, 
treatment remained unchanged. In case of refractory hyperten-
sion, defined as a sitting BP systolic >160 mm Hg or diastolic 
>100 mm Hg while the patient was already on the maximum 
combination therapy (i.e., step 4), additional strategies from 
other drug classes were instituted in order to further decrease 
BP level. Treatment decisions were taken at each visit and at 
the coordinating centre so that both the doctor and the patient 
were blinded for all study medication drugs. All drugs were 
prescribed to be taken in the morning and were supplied by the 
patient’s own pharmacist.
Adherence measurements. In all patients pill counts were per-
formed in order to calculate adherence rates. To minimize 
changes in patient’s behavior, pill counts were done out of sight 
of the patient. In a sub-population of 228 patients, recruited by 
the coordinating centre (Maastricht University Hospital) and 
surrounding general practitioners’ practices, drug intake was, in 
addition to pill counts, monitored electronically. Their adher-
ence to antihypertensive medication was measured with MEMS 
V TrackCaps (Aardex), but without giving them feedback about 
their adherence behavior. The MEMS-TrackCap is an electronic 
monitoring system designed to compile the dosing histories 
of ambulatory patients who are prescribed oral medications.11 
Microelectronics integrated into the cap of pill containers record 
the time and date that the container is opened or closed.
Statistical analysis. Baseline characteristics were defined at 
enrollment of patients (visit 1), except for baseline BP which 
was determined at visit 3 after the placebo run-in period and 
before initiation of study treatment. The 228 patients from the 
centre in which drug intake was monitored both electroni-
cally and by pill count comprised the intervention group. The 
remaining patients originating from the other three cent-
ers at which only pill count was performed acted as controls. 
Although this study was an observational study nested in a ran-
domized controlled trial, sample size calculations showed that 
at least 64 patients had to be included in both groups to detect 
a significant difference in change in BP between both groups. 
This calculation was based on a power of 80%, a significance 
level of <0.05, a minimal relevant difference in change in BP of 
10 mm Hg, with a standard deviation of 20 mm Hg.15–19
Adherence measured by MEMS was expressed as “ percentage 
of days with correct dosing”; a drug was considered to have 
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been taken correctly when the MEMS bottles were opened 
once every 24 h. Adherence measured by pill count was calcu-
lated as the percentage of the number of prescribed pills cor-
rected for the number of returned pills divided by the period 
(in days) multiplied by 100%. Defined daily doses (DDDs) of 
antihypertensive drugs were calculated according to data of the 
WHO Collaborating Centre for Drug Statistics Methodology.23 
DDDs are defined as ‘the assumed average maintenance dose 
per day for a drug used for its main indication in adults.23 
Antihypertensive drug modification was defined as an increase 
in drug dosage or adding in a new drug, or as a decrease in 
drug dosage or stopping a drug, or as a switch from one drug 
to another drug. Differences in adherence were analyzed as a 
continuous variable with the Mann–Whitney U test for non-
normally distributed data. Differences in normally distributed 
continuous variables were analyzed with the Student’s t-test. 
χ2 tests were used to compare differences in categorical vari-
ables. Logistic regression models were fitted to assess the asso-
ciation of reaching target BP (<140/90 mm Hg) and allocated 
group adjusted for the following potential confounders: study 
centre, baseline BP, patient’s age and sex, SP group, and DDDs. 
A P value smaller than 0.05 was considered to be statistically 
significant. Analyses were done on an intention-to-treat basis 
using SPSS version 15.0 (SPSS, Chicago, IL). The last observa-
tion carried forward method was applied for missing values 
when data of ≥2 consecutive visits were available.
results
In total, 510 patients met the inclusion criteria and were con-
sidered eligible for the study. Of these patients 40 withdrew or 
refused consent for various reasons. Consequently, 470 patients 
entered the study after a 4-week run-in period and started trial 
medication. Of these, 228 and 242 patients were categorized 
into the intervention and control group, respectively. Patients’ 
baseline characteristics are presented in Table 1. Differences in 
baseline characteristics between the participating centers were 
significant for age, sex, and baseline office BP (both systolic 
and diastolic BP).
In the intervention group median adherence, expressed as 
days of correct dosing, was 91.6% (Inter Quartile Range 85.7–
94.0%), whereas adherence according to pill count was 96.1% 
(Inter Quartile Range 88.8–98.4%) in this group. Patients in 
the intervention group showed an adherence determined by 
pill count which did not differ from controls (96.1% vs. 94.2%; 
P = 0.97). Based on pill count, median adherence in the total 
population to the antihypertensive drugs lisinopril, hydrochlo-
rothiazide, amlodipine, and atenolol (i.e., the drugs that were 
prescribed according to the study protocol) was 93.1%, 95.3%, 
94.9%, and 92.9%, respectively (P = 0.001).
Mean number of DDDs prescribed was higher in the 
intervention group than in the control group (2.3 vs. 1.9, 
P = 0.001). The number of DDDs prescribed for both groups 
increased throughout the study. For the periods between visit 
7 to 8 (P = 0.025), 8 to 9 (P = 0.009), and 9 to 10 (P = 0.002) 
more DDDs were prescribed for patients in the intervention 
than in the control group. The number of DDDs was posi-
tively associated with adherence to treatment determined 
by pill counts (P = 0.008), regardless of MEMS monitoring 
(P = 0.79). Table 2 presents the number of drug additions or 
dose adjustments in both groups. Of the patients in the inter-
vention group, 203 (89%) patients experienced one or more 
dose adjustments or drug additions compared to 196 (81%) 
table 1 | Baseline characteristics of the patients
Characteristic
Intervention 
(n = 228)
Control 
(n = 242) P value
age (years (s.d.)) 57 (10) 54 (11) <0.001
Male (n (%)) 112 (49) 143 (59) 0.03
Smoking (n (%)) 41 (18)c 41 (17) 0.43
alcohol (n (%)) 174 (76)b 190 (79)a 0.67
Body mass index (kg/m2 (s.d.)) 27 (4) 28 (4) 0.64
Diabetes mellitus (n (%)) 14 (6)c 10 (4) 0.43
SP group (n (%)) 114 (50) 125 (52) 0.72
Baseline office blood pressure (mm Hg (s.d.))
 Systolic 169 (21) 160 (17) <0.001
 Diastolic 99 (11) 96 (10) 0.001
number of patients on previous antihypertensive drugs (n (%))
 0 40 (18) 85 (35) <0.001
 1 86 (38) 91 (38) 0.98
 2 74 (32) 46 (20) <0.001
 3 or more 28 (12) 19 (8) 0.11
Previous antihypertensive drugs (n (%))
 Diuretics 74 (32) 77 (32) 0.88
 raS inhibitors 118 (52) 81 (33) <0.001
 β-Blockers 83 (36) 61 (25) 0.0084
 Calcium channel blockers 38 (17) 24 (10) 0.03
 α-Blockers 4 (2) 5 (2) 0.81
Data are mean (s.d.) for continuous variables and number (%) for categorical variables.
RAS, renin–angiotensin system; SP, self-pressure.
Data are missing for aone, btwo and cthree patients.
table 2 | number of drug additions or dose adjustments at the 
end of the follow-up period in the intervention and control 
group
Number of dose  
additions and/or  
increases
Number of patients with  
drugs addition and/or  
dose increase (n (%))
RRa (95% CI)
Intervention 
(n = 228)
Controls 
(n = 242)
−2 0 (0) 2 (0.8) —
−1 12 (5) 14 (6) 0.91 (0.42–1.97)
0 25 (11) 46 (19) 0.58 (0.36–0.94)
1 30 (13) 47 (19) 0.68 (0.43–1.08)
2 50 (22) 34 (14) 1.56 (1.01–2.41)
≥3 111 (49) 95 (39) 1.24 (0.94–1.63)
CI, confidence interval; RR, relative risk.
aAdjusted for systolic and diastolic blood pressure at baseline and self-pressure group.
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patients in the control group (adjusted odds ratio = 1.54; 95% 
confidence interval = 0.87–2.71). Patients who had a higher 
mean BP at baseline used more DDDs than patients who had a 
lower mean BP at baseline. This was observed in the interven-
tion as well in the control group. Differences between groups 
were statistically not significant (Figure 1).
At the end of the study, patients in the intervention group 
reached a significant higher systolic and diastolic BP than 
patients in the control group (146/86 vs. 141/85 mm Hg, 
Padjusted = 0.001 and Padjusted = 0.002 for systolic and diastolic BP, 
respectively, Table 3). Figure 2 illustrates the time course of the 
office BP during the study. Systolic and diastolic BP increased 
after visit 1 when the run-in period started and the previous 
antihypertensive medications were discontinued. After visit 3, 
systolic and diastolic BP decreased in both groups. During that 
follow-up period, systolic and diastolic BP in the intervention 
group remained significantly higher than in the control group 
with the exception of visit 6 and 8 for diastolic BP. When we sub-
tracted the achieved BP from the baseline BP, the net decrease 
in systolic and diastolic BP was comparable in both groups 
(Table 3).
Over the 12-month period, less patients in the interven-
tion group reached target BP (<140/90 mm Hg) when com-
pared to patients in the control group: 90 (40%) vs. 131 (54%), 
P = 0.001. Monitoring was associated with an odds ratio = 0.55 
(95% confidence interval = 0.38–0.80) for reaching BP con-
trol before adjustment, and an odds ratio = 0.44 (95% confi-
dence interval = 0.28–0.69) after adjustment for study centre 
(P = 0.012), age (P = 0.43), female sex (P = 0.002), systolic 
(P < 0.001) and diastolic (P = 0.004) BP at baseline, and DDDs 
 prescribed (P = 0.98).
discussion
The results from the present study suggest that BP is not better 
controlled in patients whose drug adherence is monitored elec-
tronically in addition to pill counts compared to those whose 
adherence is monitored by pill counts only. Therefore, these 
data do not support electronic monitoring of drug adherence 
as a useful tool to improve the management of hypertensive 
patients over a long period of time.
An effect of electronic monitoring on BP control may be a 
result of an increase in adherence to treatment in the interven-
tion group. Although, we did not measure adherence electron-
ically in the control group, we performed pill counts in both 
groups. Adherence according to pill counts was comparable 
in both groups. However, this result could be confounded by 
a difference in the number of DDDs prescribed between the 
intervention and control group. At the start of the HOMERUS 
trial, BP rates among patients in the intervention group were 
higher than in the control group. Consequently, the former 
used more DDDs for BP reduction. Although the number of 
DDDs was positively associated with adherence to treatment 
determined by pill counts, MEMS monitoring did not influ-
ence this association. These results may suggest that electronic 
monitoring by means of MEMS has no effect on adherence, 
resulting in comparable BP reduction rates in both groups.
In both the intervention and the control group we found a 
high median adherence according to pill counts of more than 
94%. Moreover, our results showed that an increase in DDDs 
resulted in an increase in adherence. These observations could 
be a result of our study design in which patients had to attend 
many appointments with the physician in one year of follow-
up. Recently, we have found that patients are more inclined 
to take their drugs as prescribed when they are faced with an 
upcoming consultation.24 This phenomenon, also called white-
coat compliance, underscores the importance of clinical visits 
for patients with hypertension. As a result, the absence of an 
effect of MEMS as an intervention on BP control and the high 
observed adherence may be explained by the frequent visits 
patients had to attend.
At this time, only two studies have investigated the effect of 
electronic monitoring of adherence to treatment on BP control 
in a randomized controlled setting.18,19 Wetzels and colleagues 
demonstrated that electronic monitoring reduces drug changes 
and drug use with BP control comparable to usual care.18 In 
table 3 | Blood pressure results after 12 months follow-up in 
intervention and control group
Intervention 
(n = 228)
Controls 
(n = 242) P valuea
achieved BP (mm Hg (s.d.))
 Systolic 146 (19) 141 (18) 0.001
 Diastolic 86 (10) 85 (11) 0.002
Differences between initial and achieved BP (mm Hg (s.d.))
 Systolic 23 (23) 22 (19) 0.42
 Diastolic 13 (13) 12 (11) 0.62
BP, blood pressure.
aAdjusted for systolic and diastolic BP at baseline, age, and defined daily doses.
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Figure 1 | number of DDDs prescribed during the study based on categories 
of BP (systolic/diastolic) at baseline in the intervention (dotted bars) and 
control (black bars) group. BP, blood pressure; DDD, defined daily dose. 
P value for differences between intervention and control group >0.05; P value 
for DDDs at different BP values within intervention or control group <0.05.
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contrast, we did not find an indication that electronic moni-
toring was associated with less drug changes and drug use. In 
our study the number of DDDs used was based on the initial 
BP at baseline. Recently, Santschi and colleagues demonstrated 
that electronic monitoring led to better BP control, however 
the effect decreased over time.19 In that 12 months follow-
up study, adherence rates were discussed with the patients, 
thereby possibly influencing the true effect of electronic moni-
toring on BP control. Given our results, the effect observed in 
Santschi’s study may be attributable solely to the feedback pro-
vided by physicians to patients.
The results of our study must be interpreted within the con-
text of its limitations. First of all, this study was not designed 
as a randomized controlled trial. In addition, the analysis was 
not powered to investigate differences between the interven-
tion and control group. Adherence to treatment was measured 
electronically in a group of patients from the HOMERUS trial. 
The remaining population officiated as controls. Although, 
imbalances were observed in baseline characteristics between 
the intervention and control group, adjusting for these differ-
ences in a multivariate model had no effect on the association 
between electronic monitoring and BP control. It is therefore 
less likely that the study design influenced our results. Second, 
all patients in this study were aware that their adherence was 
being monitored, either by MEMS or by pill counts. In addi-
tion, patients had many appointments to attend with the phy-
sician within 1 year of follow-up. This may have resulted in a 
greater adherence than what is usually seen in the general pop-
ulation and, hence, overestimation of the habitual adherence 
of these subjects. Although, ideally, one would prefer not to 
inform patients that their adherence is being measured, ethical 
considerations preclude such an approach.
The extraordinary high adherence rate in the present study 
may complicate extrapolation of these results to the population 
at large. However, this high adherence rate does not necessarily 
imply that the study participants and/or their adherence behav-
ior deviate from those in other studies. The two randomized 
studies performed by Wetzels and Santschi also showed adher-
ence levels of more than 90%.18,19 In these studies the effect 
of electronic monitoring on BP reduction was only noticeable 
in the first months of the study. Several observational studies 
showed that electronic monitoring significantly decreases BP. 
Despite comparable adherence levels between those studies 
and our study, the follow-up period was shorter when com-
pared to our study (3–6 months vs. 12 months).15–17 Given 
our results and the long-term results observed by Santschi and 
colleagues,19 it is likely that an effect of electronic monitor-
ing on BP diminishes when patients are followed for a longer 
period. It is however not known whether this effect is different 
in patients who are less adherent than patients in the described 
studies. Future studies should elucidate this.
Recently, we investigated whether deviant drug intake 
behavior occurred by comparing MEMS data and pill count 
data.25 In that report we showed that deviant intake behavior 
occurred frequently but that this did not necessarily led to dif-
ferences in BP control between groups. Consequently, we con-
cluded that pill count could be a useful adjunct to MEMS caps 
for exploring deviant intake behavior. Furthermore, we stated 
that counting pills in adjunct to MEMS registration should 
be performed to identify true nonadherers. In the present 
study, we compared the 228 patients that were also included 
in the previous article with a population that did not partici-
pate in the previous study. The results of our previous paper 
and the present one can best be summarized as follows: today, 
none of the methods that are applied to monitor adherence to 
treatment is ideal and each has its specific shortcomings. Of 
the available methods MEMS seems to be the best, primarily 
because it provides hard data. Those hard data, however, refer 
only to the monitoring of the exact dates and times the patient 
is concerned with his or her medication. It does not give insight 
into the actual taking of the medication. Consequently, we 
previously recommended to combine MEMS with pill count. 
Nevertheless, whatever method one applies, it does not corre-
late very well with achieved BPs. This means that either all our 
methods, including MEMS, are fraught with error or there is 
more to reaching an acceptable BP level than adherence alone.
Taking our data together, our findings do not support the 
hypotheses that electronic monitoring by means of MEMS 
leads to better BP control or that it results in less drug changes 
and drug use. This may be due to the high overall adherence 
we have observed in our study as a consequence of the specific 
study design.
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Figure 2 | Time course of systolic and diastolic blood pressure (BP) in the intervention (open circles) and control (closed circles) group. Differences in systolic BP 
between the intervention and control group are significant at all visits; differences in diastolic BP between the intervention and control group are significant at 
all visits, except at visit 1, 2, 6, and 8.
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